Posted on

Lateral flow urine lipoarabinomannan assay (LF-LAM) for diagnosis of active tuberculosis infection in human immunodeficiency virus (HIV) patient

General Track – Cycle 2 | Clinical Equipment and Devices

HTA Council Recommendation (as of 9 July 2025)

The HTA Council positively recommends the government financing of Lateral flow urine lipoarabinomannan assay (LF-LAM) for diagnosis of active tuberculosis infection in human immunodeficiency virus (HIV) patient

The HTA Council recommends that the Department of Health refer to existing and future WHO target product profiles (TPPs) when selecting tests for procurement. In the absence of target product profiles, WHO prequalification may be used as a requirement to ensure the quality of the test to be procured.

(See below for more details)

Relevant Information

  1. Status: With Final HTA Council Recommendation
  2. Topic Assignment: Internal Assessment
  3. Policy Question: Should Lateral flow urine lipoarabinomannan assay (LF-LAM) for diagnosis of active tuberculosis infection in human immunodeficiency virus (HIV) patient be funded by the government?
  4. Secretary of Health Decision: Approved for government financing

Evidence and Relevant Documents

Back to Assessments Page